News

Due to the increased use of illicit fentanyl mixed with heroin and used in counterfeit prescription drugs, the DEA placed all illicit fentanyl analogues not already regulated by the Controlled Substances Act into Schedule I.

Understanding the key barriers to biosimilar adoption in the U.S. is the first step managed care executives can take to overcome these obstacles, according to a Trinity Parners report.